AMENDMENTS TO THE CLAIMS

1. – 38. (Canceled)

39. (Currently Amended) A method of increasing the lethal dose of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide to twice or more, reducing the toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide, reducing gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide, reducing hepatic toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide, and/or reducing cardiovascular toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide ~~for treatment of tumors~~, which comprises administering to a subject in need thereof a composition comprising

(a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and

(b) (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof.

40. (Previously Presented) The method according to Claim 39, wherein said subject in need thereof is a human.

41. (Previously Presented) The method according to Claim 39, wherein said effective amount of said (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof ranges from 0.1-10000mg per day.

42. (Previously Presented) The method according to Claim 39, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

43. – 49. (Canceled)

50. (Previously Presented) The method according to Claim 39, wherein (a) and (b) are administered simultaneously.

51. (Previously Presented) The method according to Claim 39, wherein (a) and (b) are administered sequentially.

52. (Previously Presented) The method according to Claim 39, wherein (a) is Dexamethasone.

53. (Previously Presented) The method according to Claim 39, wherein (a) is an ester of Dexamethasone.

54. (Previously Presented) The method according to Claim 39, wherein (a) is a salt of Dexamethasone.

55. (Previously Presented) The method according to Claim 39, wherein (b) is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

56. (Previously Presented) The method according to Claim 39, wherein (b) is a salt of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

57. (New) The method according to Claim 39, wherein said method is a method of increasing the lethal dose of AC-7700 to twice or more.

58. (New) The method according to Claim 39, wherein said method is a method of reducing the toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

59. (New) The method according to Claim 39, wherein said method is a method of reducing gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

60. (New) The method according to Claim 59, wherein said gastrointestinal toxicity is diarrhea.

61. (New) The method according to Claim 39, wherein said method is a method of reducing hepatic toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

62. (New) The method according to Claim 61, wherein said reducing hepatic toxicity is lowering of GPT.

63. (New) The method according to Claim 39, wherein said method is a method of reducing cardiovascular toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

64. (New) The method according to Claim 63, wherein said reducing cardiovascular toxicity is lowering of CPK.